|View printer-friendly version|
Spring Bank to Present Additional Data from the First Cohort of its Ongoing SB 9200 ACHIEVE Clinical Trial at the 2017 International HBV Meeting in Washington D.C.
The Satellite Symposium, organized by Dr.
Abstract #112526: Phase IIa ACHIEVE Clinical Trial of SB 9200: Results from the Tenofovir Switch Segment of the 25mg Cohort, MF Yuen et al.
The ongoing ACHIEVE trial is a placebo-controlled phase 2 study of SB 9200 in HBV treatment-naïve patients. Each cohort receives 12 weeks of monotherapy with SB 9200 at doses of 25mg, 50mg, 100mg, 200mg or placebo and is then subsequently switched to tenofovir1 300mg (TDF) daily for 12 weeks (week 12 – 24). Spring Bank previously reported top-line results showing that the low dose (25mg) of SB 9200 alone showed a favorable safety profile and antiviral activity against HBV DNA and HBsAg. Administration of SB 9200 resulted in a statistically significant reduction in HBV DNA at week 12 (unpaired t-test 2.85, p=0.01) compared to placebo, with a mean reduction of 0.6 log10 (range 0 to 1.87 log10) in the SB 9200 treatment group. Complete data on the full 25mg cohort after the switch to TDF will be presented at the Satellite Symposium.
Following the company’s presentation of the abstract, a copy of presentation materials can be accessed by visiting the Investors & Media section of the company’s website at www.springbankpharm.com and selecting “Presentations.”
For more information on the International HBV Meeting refer to http://www.hbvmeeting.org/
Statements in this press release about Spring Bank's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Spring Bank’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether Spring Bank’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether the results of such trials will warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether Spring Bank's product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of Spring Bank's Annual Report on Form 10-K for the year ended December 31, 2016, which was filed with the Securities and Exchange Commission (
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof. Spring Bank anticipates that subsequent events and developments will cause Spring Bank’s views to change. However, while Spring Bank may elect to update these forward-looking statements at some point in the future, Spring Bank specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spring Bank’s views as of any date subsequent to the date hereof.
1. Gilead Sciences’ Viread®
Contacts For investor inquires: